Search research articles
Contact Us
Filters
Showing results (31-40 of 94) with videos related to
Page
of 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2012
Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers
Snjezana Dogan, Ronglai Shen, Daphne C Ang, et al.
JCO Precision Oncology
|
December 5, 2025
Clinical Presentation of <i>MTAP</i> Deletions in Real-World Settings: Lessons for the Clinical Development of Novel Targeted Therapies
Jordan T Best, Xiaotong Fu, Sripraharsha S Jampana Raju, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 18, 2011
A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations
Gregory J Riely, Melissa L Johnson, Chanoa Medina, et al.
British Journal of Cancer
|
March 4, 2023
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours
Melissa L Johnson, Judy S Wang, Gerald Falchook, et al.
Plos One
|
January 6, 2016
Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers
Bob T Li, Emil Lou, Meier Hsu, et al.
Cell Reports. Medicine
|
March 7, 2025
Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies
Juanita S Lopez, Mohammed Milhem, Marcus O Butler, et al.
Journal for Immunotherapy of Cancer
|
December 6, 2019
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors
Ezra E W Cohen, Michael J Pishvaian, Dale R Shepard, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 14, 2026
Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1-high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part1
Jarushka Naidoo, Solange Peters, Yotsawaj Runglodvatana, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 2, 2021
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC
Jyoti Malhotra, Petros Nikolinakos, Ticiana Leal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2025
Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial
Charles M Rudin, Melissa L Johnson, Luis Paz-Ares, et al.
Page
of 10
Search research articles
Search
Showing results (31-40 of 94) with videos related to
Sort By:
Page
of 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2012
Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers
Snjezana Dogan, Ronglai Shen, Daphne C Ang, et al.
JCO Precision Oncology
|
December 5, 2025
Clinical Presentation of <i>MTAP</i> Deletions in Real-World Settings: Lessons for the Clinical Development of Novel Targeted Therapies
Jordan T Best, Xiaotong Fu, Sripraharsha S Jampana Raju, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 18, 2011
A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations
Gregory J Riely, Melissa L Johnson, Chanoa Medina, et al.
British Journal of Cancer
|
March 4, 2023
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours
Melissa L Johnson, Judy S Wang, Gerald Falchook, et al.
Plos One
|
January 6, 2016
Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers
Bob T Li, Emil Lou, Meier Hsu, et al.
Cell Reports. Medicine
|
March 7, 2025
Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies
Juanita S Lopez, Mohammed Milhem, Marcus O Butler, et al.
Journal for Immunotherapy of Cancer
|
December 6, 2019
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors
Ezra E W Cohen, Michael J Pishvaian, Dale R Shepard, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 14, 2026
Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1-high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part1
Jarushka Naidoo, Solange Peters, Yotsawaj Runglodvatana, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 2, 2021
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC
Jyoti Malhotra, Petros Nikolinakos, Ticiana Leal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2025
Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial
Charles M Rudin, Melissa L Johnson, Luis Paz-Ares, et al.
Page
of 10